Peptide Schedule
Bivalirudin (Angiomax)20 residuesFPRPGGGGNGDFEEIPEEYLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bivalirudin (Angiomax) Dosage Calculator
Bivalirudin (brand name Angiomax) is a synthetic 20-amino-acid peptide that functions as a specific, reversible direct thrombin inhibitor (DTI).
0.75mcg · Single dose
Summary: Add 0mL BAC water to your 250mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.75mcg dose. This vial will last 0 doses.
Cycle Planner
Bivalirudin (Angiomax) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 25 minutes (normal renal function); 34-57 minutes (moderate-severe renal impairment); 3.5 hours (dialysis patients)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Bivalirudin (Angiomax) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.75mg | Single dose |
| Moderate | 0.75mg | Single dose |
| Aggressive | 0.75mg | Single dose |
Note: Bivalirudin is an FDA-approved direct thrombin inhibitor administered exclusively in hospital settings during percutaneous coronary intervention (PCI). Dosing is weight-based: a 0.75 mg/kg IV bolus followed by a continuous infusion of 1.75 mg/kg/h for the duration of the procedure. For STEMI patients, the infusion may be extended up to 4 hours post-PCI at 1.75 mg/kg/h to reduce acute stent thrombosis risk. Renal dose adjustment is required: reduce infusion to 1 mg/kg/h for CrCl <30 mL/min, and 0.25 mg/kg/h for dialysis patients. Activated clotting time (ACT) should be checked 5 minutes after the bolus; an additional 0.3 mg/kg bolus may be given if ACT is subtherapeutic. This is not a self-administered peptide — it is used exclusively under direct medical supervision in catheterization laboratories and ICU settings.
About Bivalirudin (Angiomax)
Bivalirudin (brand name Angiomax) is a synthetic 20-amino-acid peptide that functions as a specific, reversible direct thrombin inhibitor (DTI). Originally derived from hirudin, the naturally occurring anticoagulant found in the saliva of the medicinal leech Hirudo medicinalis, bivalirudin was engineered to retain potent antithrombotic activity while offering a more predictable pharmacokinetic profile. The peptide received FDA approval in 2000 for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including those with or at risk of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). Unlike heparin, bivalirudin does not bind to platelet factor 4, eliminating the risk of triggering HIT — a potentially life-threatening immune-mediated complication. Bivalirudin exhibits bivalent binding to thrombin, simultaneously engaging both the catalytic active site and the anion-binding exosite-1. This dual-site interaction provides potent inhibition of both circulating (free) and clot-bound (fibrin-bound) thrombin, an advantage over heparin which can only inhibit circulating thrombin. The binding is reversible because thrombin itself slowly cleaves the bivalirudin Arg3-Pro4 peptide bond, gradually restoring thrombin enzymatic function. Landmark clinical trials including HORIZONS-AMI, EUROMAX, BRIGHT, and BRIGHT-4 have established bivalirudin as a key anticoagulation option during primary PCI for ST-elevation myocardial infarction (STEMI). The HORIZONS-AMI trial demonstrated reduced 30-day major bleeding (4.9% vs 8.3%) and lower all-cause mortality (2.1% vs 3.1%) compared to heparin plus glycoprotein IIb/IIIa inhibitors. The BRIGHT-4 trial further showed that bivalirudin with extended post-PCI infusion reduced both bleeding and stent thrombosis compared to heparin monotherapy. With a half-life of approximately 25 minutes and predominant elimination through proteolytic cleavage rather than hepatic or renal metabolism, bivalirudin offers a rapid onset-offset profile that is particularly valuable in the acute interventional cardiology setting where precise anticoagulation control is critical.